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Botswana120 during the ﬁrst year after seroconversion in HIV-1 subtype C infection was
addressed in a case series of eight subjects. Multiple viral variants were found in two out of eight cases. Slow
rate of viral RNA decline and high early viral RNA set point were associated with a higher level of proviral
diversity from 0 to 200 days after seroconversion. Proviral divergence from MRCA over the same period also
differed between subjects with slow and fast decline of viral RNA, suggesting that evolution of proviral gp120
early in infection may be linked to the level of viral RNA replication. Changes in the length of variable loops
were minimal, and length reduction was more common than length increase. Potential N-linked
glycosylation sites ranged ±one site, showing common ﬂuctuations in the V4 and V5 loops. These results
highlight the role of proviral gp120 diversity and diversiﬁcation in the pathogenesis of acute HIV-1 subtype C
infection.
© 2008 Elsevier Inc. All rights reserved.IntroductionAfter decades of endemic evolution, HIV-1 has achieved enormous
diversity in the worldwide HIV/AIDS epidemic, posing a signiﬁcant
challenge for anHIV vaccine design. A complex interplay betweenvirus
and host during HIV-1 infection results in the gradual accumulation of
provirus variants. The constantly growing repertoire of archived
proviral sequences represents a history of virus replication within
the host, providing a continuous source for subsequent HIV replication
and transmission. Despite the signiﬁcant fraction of proviral DNA
represented by replication-deﬁcient sequences, the archived virus has
an enormous potential for viral complementation and survival as a
pool of viral quasispecies. It is likely that the amount of integrated
provirus and extent of its diversity play important role in establishing
and maintaining dual, triple and superinfections. Therefore, the
contribution of accumulating provirus to the increase of viral diversity
in the course of HIV-1 infection should not be underestimated.
A diverse distribution of HIV-1 subtypes within the HIV/AIDS
epidemic has resulted in worldwide dominance by HIV-1 subtype C
(Hemelaar et al., 2006; McCutchan, 2006; Osmanov et al., 2002). It is
believed that the highest incidence and prevalence of HIV-1 infectionth AIDS Initiative, FXB 402, 651
739 8348.
@hsph.harvard.edu (M. Essex).
l rights reserved.in the world is caused by subtype C in southern African countries.
Signiﬁcant progress has been made recently in studying HIV-1
subtype C (Bredell et al., 2007; Coetzer et al., 2007; Ndung'u, Renjifo,
and Essex, 2001; Ndung'u et al., 2000, 2006; Novitsky et al., 2002a,
2001a, 2003, 2001b, 2002b, 2007a; Rademeyer et al., 2004; Rong et al.,
2007a; van Harmelen et al., 1998, 2001, 1997, 1999; Williamson et al.,
1995, 2003; Williamson, 2003; Zhang et al., 2005, 2006), providing
strong evidence for subtype-speciﬁc differences on genetic and
functional levels (Gnanakaran et al., 2007; Li et al., 2006a; Rademeyer
et al., 2007; Rong et al., 2007b). However only few recent studies
addressed viral quasispecies in HIV-1 subtype C infection (Rong et al.,
2007a; Rousseau et al., 2008; Salazar-Gonzalez et al., 2008). Lingering
evolution of subtype C quasispecies is understudied, at least as
compared with a series of comprehensive studies on evolution of
subtype B viruses (Delwart et al., 2002; Freel et al., 2003; Frost et al.,
2005; Gottlieb et al., 2008; Herbeck et al., 2006; Keele et al., 2008;
Learn et al., 2002; Leitner, Kumar, and Albert, 1997; Ritola et al., 2004;
Shankarappa et al., 1999). A thorough analysis of the sequence of
transmitted viruses and the structures of their envelopes may yield
clues to help guide vaccine design (Johnston and Fauci, 2007).
It is believed that the population of viral quasispecies in acute
HIV-1 infection is relatively uniform; however both homogeneous and
heterogeneous virus populations have been reported at or soon after
virus transmission (Delwart et al., 1994; Gottlieb et al., 2007a, 2008;
Keele et al., 2008; Learn et al., 2002; Long et al., 2000; Markham et al.,
48 V. Novitsky et al. / Virology 383 (2009) 47–591998; Poss et al., 1995; Salazar-Gonzalez et al., 2008; Shankarappa
et al., 1999; Wolfs et al., 1992; Zhang et al., 1993; Zhu et al., 1993). A
linear increase of viral diversity was estimated at the level of about 1%
per year in the C2–V5 region of HIV-1 subtype B env (Herbeck et al.,
2006; Shankarappa et al., 1999).
Selection pressure is distributed unevenly across HIV-1 Env
(Choisy et al., 2004; Gaschen et al., 2002) with clear subtype-speciﬁc
differences (Gnanakaran et al., 2007). In HIV-1 subtype C, the C3
region of gp120 includes the highly variable α2-helix and, together
with the V4 region, was shown to be the main target for early
neutralizing antibodies (NeuAb) (Moore et al., 2008). Shorter lengths
of V1–V5 loops and fewer glycosylation sites, particularly in the V1–
V2 region, were associated with development of early strain-speciﬁc
NeuAb (Gray et al., 2007). The number of potential N-linked
glycosylation sites (PNGS) and the sequence length of the C2–V5
region of Env were shown to be relatively stable in infants infected
with HIV-1 subtype C (Zhang et al., 2005).
The goals of this case series study were to characterize the
evolution of gp120 in acute subtype C infection, to test whether viral
diversity and diversiﬁcation differ between viral RNA load phenotypes
of slow and fast decline, and to evaluate changes in the length of
variable loops and the number of PNGS in acute HIV-1 subtype C
infection in adults.
Results
Two distinct viral RNA phenotypes were evident at the very early
stage of HIV-1 subtype C infection (Fig. 1A, individual curves of viral
RNA load, and 1B, early viral RNA set point). The line of evidence for
viral RNA phenotypes included the following: 1) differences in decline
of viral RNA from peak between groups was conﬁrmed by levels of
viral RNA and slopes of viral RNA decline within ﬁrst 2 months post-
seroconversion; 2) differences in the level of an early viral RNA set
point from 50 to 200 days post-seroconversion; 3) differences in the
levels of CD4+ T cell counts; and 4) difference in decline of CD4+ Tcells
below 200 within 1 year after seroconversion. The observed
phenotypes of viral RNA, namely slow and fast decline of viral RNA,
provided a rationale for looking for potential differences in early viral
evolution among subjects experiencing either slow or fast decline of
viral RNA at early stage of HIV-1 infection. We hypothesized that viral
diversity and diversiﬁcation are higher in subjects with slow decline of
viral RNA and high early viral RNA set point. Conversely, subjects with
fast decline of viral RNA and a low level of early viral RNA set point
have lower viral diversity and diversiﬁcation.
Phylogenetic relationships
All eight subjects in this study were infected by HIV-1 subtype C,
which was evident by clustering with four HIV-1 subtype C references
(Fig. 2). Clustering with subtype C references was supported in the NJ
analysis by bootstrap value of 100 (data not shown). The evolutionary
history of proviral sequences was inferred by the maximum likelihood
method. As expected, viral quasispecies belonging to different
subjects formed distinct clusters (Fig. 2). Subjects with slow decline
of viral RNA and a high early viral RNA set point (shown in red)
generally had longer and more diversiﬁed branches while subjects
with fast decline and low early viral RNA set point (shown in green)
demonstrated more compact branches in the phylogenetic tree. Two
subjects from the group with slow decline of viral RNA, 1811 and 5018
demonstrated distinct intra-patient clusters of quasispecies sugges-
ting a potential infection with more than a single viral variant. The
topology of viral sequences along the branches connecting two intra-
patient clusters suggested a potential recombination between viral
quasispecies belonging to different clusters.
To test the possibility of dual infection, genetic pairwise distances
between subjects' MRCA were compared with intra-patient distancesincluding total and intra-cluster distances for cases 1811 and 5018 (Fig.
3). Distances between subjects' MRCA had a mean of 25.2%±3.2%
ranging from 18.3% to 30.5%. The total intra-patient distances in 1811
and 5018 were 3.3%±2.3% and 1.7%±1.7%, respectively, while intra-
cluster distances were 0.8%±0.5% and 0.7%±0.5% in subject 1811, and
0.4%±0.5% and 1.1%±0.3% in subject 5018. Not surprisingly, the
pairwise intra-patient distances between clusters accounted for the
upmost level of viral intra-patient diversity and were 5.9%±0.5% and
4.1%±0.4% in 1811 and 5018, respectively. All intra-patient distances in
cases 1811 and 5018 were signiﬁcantly lower than inter-patient
distances (pb0.001 for all comparisons). Therefore, the comparison of
inter- and intra-patients distances, and the branch topology in the
phylogenetic tree provided evidence that subjects 1811 and 5018 are
unlikely to be dually infected with distinct unrelated viral isolates. In
contrast, both cases 1811 and 5018 are more likely to represent HIV-1
infection with more than a single viral variant that apparently
originated from the pool of diversiﬁed viruses at the time of
transmission or multiple transmission events from the same (per
subject) donor.
We tested 1811 or 5018 sequences for potential recombinants. The
presence of breakpoint in bootstrap sliding window analysis was used
as criteria for recombination. The branch topology allowed us to
identify potential candidates located in-between clusters that are
likely to represent recombinants between clusters. In case 1811, ten
sequences originating from 91 to 350 days after seroconversion were
identiﬁed as potential recombinants (Fig. 4A). In nine cases break-
points were identiﬁed and these sequences were classiﬁed as
recombinants. No evidence for recombination was found in a single
sequence 350.08. The location of breakpoints was not uniform
suggesting a number of independent recombination events. The
breakpoints at the end of V3 loop and on the edge of C3 region and V4
loop were observed in multiple viral variants. A total of eight
sequences were tested for potential recombination in subject 5018
(Fig. 4B). Only two sequences sampled at day 97 after seroconversion
demonstrated breakpoints. None of the remaining sequences tested
provided evidence for recombination.
The overall topology of gp120 sequences in subject 1811 suggested
a congruent evolution of viral quasispecies within two clusters
accompanied by recombination of viral variants between clusters.
Interestingly, the cluster 2 was represented by a minor viral variant at
16 days but by a major variant at 97 days, implying a dynamic
interplay between apparent immune pressure and virus over the ﬁrst
3 months after seroconversion. In subject 5018, viral variants
representing the seroconversion sequences (shown by a diamond)
were evident in cluster 1, but were not seen in cluster 2. It is possible
that viral variants representing cluster 2 did exist at the time of
seroconversion but were not ampliﬁed apparently due to a low copy
number.
Diversity and diversiﬁcation
Viral population heterogeneity of the proviral gp120 was studied
prospectively over the ﬁrst year after seroconversion (Fig. 5A). The
population of proviral quasispecies was relatively homogeneous at
seroconversion evident from a mean value of 0.21%±0.15% and a tight
range from 0.015 to 0.36% in most subjects except the case 1811
infected with more than a single viral variant. At day 16, the overall
diversity in subject 1811 was 1.45%±2.24% but only 0.35%±0.23%
within cluster 1 (no data for cluster 2 because a single sequence
available at day 16). At seroconversion, the extent of proviral diversity
did not differ between subjects with slow and fast decline of viral RNA
(p=0.18 and p=0.09 for uncorrected and cluster-corrected compar-
isons). However after seroconversion, proviral diversity in gp120
varied between subjects and the difference reached statistical
signiﬁcance between groups with different viral RNA phenotype.
Fig. 5B demonstrates that proviral diversity in subjects with slow
Fig. 1. Viral RNA load in acute HIV-1 subtype C infection. (A) Individual curves of viral RNA load in eight cases of acute infection. The timeline shows days from detected
seroconversion. Time 0 corresponds to the ﬁrst seropositive test. Plasma viral RNA load is expressed as log10 copies perml of plasma. Measurements of viral RNA before time 0 are pre-
seroconversion. Numbers at top of boxes correspond to subject cases. Dotted lines with arrows indicate initiation of ART. (B) Early viral RNA set point in acute HIV-1 subtype C
infection. The level of viral RNA at early set point was deﬁned as a mean±standard deviation of measurements from 50 to 200 days from detected seroconversion (after assuming
reduction of viral RNA peak). N shows the number of viral RNAmeasurements for the period from 50 to 200 days per subject. Dashed line shows a median of early viral RNA set point
computed for all eight subjects at 4.53 log10 copies/ml. The ﬁrst four subjects 1811, 2865, 3312, and 5018 correspond to the group of slow decline of viral RNA and high early viral RNA
set point. Subjects 3430, 3505, 3603, and 5582 correspond to the group of fast decline of viral RNA and low early viral RNA set point.
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RNA load. During the ﬁrst 200 days after seroconversion, the mean
diversity was 0.24%±0.18% in the group with fast decline of viral RNA,
while it was 1.40%±0.65% and 0.73%±0.22% for uncorrected and
cluster-corrected distances in the groupwith slow decline of viral RNA
(Fig. 5C; p=0.029 and p=0.006 for uncorrected and cluster-corrected
comparison, respectively). However, the signiﬁcance between groups
was lost at later time points, in part, probably due to increasedﬂuctuations apparent from high standard deviations in groups (Fig.
5C; 201+ days comparisons). A gradual increase of proviral diversity
was evident by positive slopes in all subjects by 200 days after
seroconversion, ranging from 7.6E-06 in subject 3603 to 2.0E-04 in
subject 1811. Slopes of proviral diversity differed between groups of
viral RNA phenotypes andwere higher in subjects with slow decline of
viral RNA for the period 0 to 200 days after seroconversion (p=0.031).
By the end of the ﬁrst year of infection the mean diversity of proviral
Fig. 2. Phylogenetic relationships of gp120 sequences in acute HIV-1 subtype C infection. A phylogenetic tree was generated by PhyML (Guindon and Gascuel, 2003) using the HKY
model for nucleotide substitution, and visualized in FigTree v.1.1.2 (Rambaut, 2008). Main branches are labeled with subjects' numbers. Coloring corresponds to the viral RNA
phenotypes: subjects with slow decline of viral RNA and a high early viral RNA set point are shown in red, and subjects with fast decline of viral RNA and a low early viral RNA set
point are shown in green. Clusters are highlighted for subjects 1811 and 5018. HIV-1 subtype reference sequences are shown in blue. The cluster of all HIV-1 M group non-subtype C
references is shown at the bottom.
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Fig. 3. A comparison of inter-patient viral diversity in 8 subjects and intra-patient
diversity in subjects 1811 and 5018. Pairwise maximum likelihood distances are shown.
The inter-patient viral diversity was quantiﬁed as pairwise distances between MRCA of
8 subjects. The intra-patient diversity was measured as pairwise distances between
viral quasispecies within each subject or each cluster. Distance between clusters were
compared by quantifying pairwise distances between sequences belonging to each
cluster. In the box plots: the boundary of the box closest to zero indicates the 25th
percentile, a solid line within the box marks the median value, a dashed line within the
box shows the mean, and the boundary of the box farthest from zero indicates the 75th
percentile. Whiskers above and below the box indicate the 10th and 90th percentiles.
Points above and below the whiskers indicate outliers outside the 10th and 90th
percentiles.
51V. Novitsky et al. / Virology 383 (2009) 47–59quasispecies in gp120 increased to 1.72%±1.04% for uncorrected and
1.32%±0.76% for the cluster-corrected distances. The diversity was
higher in the group with slow decline of viral RNA at the time period
301+ days in the uncorrected analysis (p=0.015; 95% CI for difference
of means 0.54 to 2.87) but was not seen in the cluster-corrected
analysis (pN0.05).
The shape of viral diversiﬁcation resembled graphs of viral
diversity (Fig. 6A). The mean diversiﬁcation of viral quasispecies
from MRCA for the period from 0 to 200 days after seroconversion
was 1.02%±1.04% and 0.89%±0.86% for uncorrected and cluster-
corrected distances, respectively. For the later time points, the mean
diversity from MRCA increased to 1.25%±0.79% and 1.57%±1.17% for
uncorrected and cluster-corrected distances, respectively. This was
close but a little higher than the previously reported 1%-per-year
increase of env C2V5 diversity in HIV-1 subtype B infection (Herbeck
et al., 2006; Shankarappa et al., 1999). Similarly to proviral diversity,
viral diversiﬁcation from MRCA differed between the viral RNA
phenotypes. During 0 to 200 days after seroconversion diversity from
MRCA reached 1.74%±1.04% and 2.01%±1.40% for uncorrected and
corrected distances in the group with slow decline of viremia, while
remaining at mean of 0.30%±0.22% in subjects with fast decline of
viral RNA load (Fig. 6B; p=0.029 and p=0.044 for uncorrected and
cluster-corrected comparisons). At later time points, only a trend to a
higher viral diversiﬁcation from MRCA was observed in the group
with slow decline of viral load (p=0.095 and p=0.079 for uncorrected
and cluster-corrected comparisons), which can be attributable to
higher inter-patient variation and relatively small sample size.
Length of variable loops and number of PNGS
To address changes in length of variable loops in proviral gp120, we
quantiﬁed the amino acid length of ﬁve variable loops and C3 regionover the ﬁrst year of infection and computed the difference in amino
acid length from the time of seroconversion (Fig. 7A). We found no or
minimal change in the length of variable loops in HIV-1 subtype C
infection over the ﬁrst year after seroconversion. The V1 loop was
predominantly reduced, which was evident by negative slopes in ﬁve
out of eight subjects. In the V2 loop, three cases had a slight increase,
while three subjects had no length change and two had decreases in
length. The length of the V3 loop and the C3 region virtually did not
change over the ﬁrst year of infection. The V4 loopwas reduced in two
cases of infectionwithmultiple viral variants (subjects 1811 and 5018),
and was almost unchanged in the other six subjects. The V5 loop
length was unchanged in three, decreased in four, and increased in
one subject. Interestingly, while there were minimal or no change in
length of variable loops within clusters (cases 1811 and 5018), the
length of variable loops differed between clusters. For example,
clusters in subject 1811 showed lengths of 26 and 22 aa in V1, 48 and
43 aa in V2, 52 and 51 aa in C3 region, and 30–31 and 26 aa in V4.
Clusters in subject 5018 were different only in V4 loop, demonstrating
lengths of 29 and 26 aa. No difference in the V-loop length was found
between groups with slow and fast decline of viral load (data not
shown).
The number of PNGS was relatively stable and the mean values
ﬂuctuated within ±one amino acid within the ﬁrst year of HIV-1
subtype C infection (Fig. 7B). The overall pattern of changes in the
number of PNGS was similar to the amino acid length changes over
time. The number of PNGS in the V1 loop showed negative slopes in
ﬁve out of eight cases. Changes in the V2 and V3 loops were minimal.
In the C3 region, an increase of the number of PNGS was seen in four
out of eight subjects including subject 3505 who increased the
number of PNGS gradually from 2 to 3 over the ﬁrst year of infection.
In the V4 loop, the number of PNGS increased in 3 subjects, stayed
unchanged in one subject, and decreased in 4 cases. The number of
PNGS in the V5 loop showed an increase in 3 cases, stayed unchanged
in 2 cases, and decreased in 3 cases. Some differences between the
number of PNGS were observed between clusters in subjects 1811 but
not in subject 5018. Thus, clusters in subject 1811 had 3 and 2 PNGS in
V2, 2 and 3 PNGS in C3 region, 4 and 3 PNGS in V4, and did not differ in
V1, V3, and V5 loops. No signiﬁcant differences in the number of PNGS
between groups with slow and fast decrease of viral load were found
(data not shown).
Discussion
A better understanding of early events in HIV-1 subtype C infection
may facilitate proper intervention strategies and better vaccine
design. We analyzed the evolution of proviral quasispecies in the
V1C5 region of gp120 during the ﬁrst post-seroconversion year in
eight acute cases of HIV-1 subtype C infection from Botswana. Despite
the inherent limitations of a small sample set, the results of this study
provide evidence that viral evolution in subtype C infection might
have some speciﬁc characteristics. First, infection with more than a
single viral variant is not rare in HIV-1 subtype C infection. Second,
early viral RNA set point from 50 to 200 days post-seroconversion
seems to be associated, at least temporarily, with proviral diversity
and diversiﬁcation in subtype C gp120. Third, no pattern of increase in
the length of variable loops was observed. Fourth, the increase in the
number of PNGS in proviral gp120 was clearly not a dominant pattern
of viral evolution over the ﬁrst post-seroconversion year.
Two out of eight subjects in this study were infected with more
than a single variant of subtype C viruses. Dual infections originating
from multiple transmissions of non-related viruses from multiple
donors (“multiple donors to a single recipient transmission”) were
ruled out based on phylogenetic analysis and comparison of inter- and
intra-patient pairwise distances. The most plausible explanation of
cases 1811 and 5018 is a transmission of diversiﬁed viral variants from
a single (per subject) donor. Multiple transmissions from the same
Fig. 4. Analysis for potential recombination in subjects 1811 and 5018. Distinct clusters and potential recombinants are deﬁned. Each sequence is shown by a symbol corresponding to
time points of sampling followed by number of days from detected seroconversion and ID of viral quasispecies. The recombinant search was performed by bootstrap analysis in the
SimPlot program (Lole et al., 1999). The HIV-1 group M ancestor sequence was used as outlier (blue line). Arrows on the top of bootstrap graphs designate potential breakpoints of
recombination between viral variants. The location of variable loops in gp120 is shaded. (A) Subject 1811. Time points of sampling are shown by a diamond at 16 days, a triangle to the
bottom at 91 days, a circle at 260 days, and a square at 350 days. The 16 day sequences in cluster 1 and sequence 016.01 were used as references for the ﬁrst (red) and second (green)
clusters. The red and green lines correspond to bootstrap values per sliding window. (B) Subject 5018. Time points of sampling are designated by a diamond at day 0, a triangle to the
bottom at 97 days, a circle at 171 days, a triangle to the top at 203 days, a cross at 295 days, and a square at 387 days. The 0 time point sequences in cluster 1 and majority consensus
sequence for the entire cluster 2 were used as references for the ﬁrst and second cluster (red and green lines correspond to bootstrap values, respectively).
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Fig. 4 (continued).
53V. Novitsky et al. / Virology 383 (2009) 47–59donor occurring over time cannot be ruled out, and apparently are
likely to happen. Both cases of infection with more than a single viral
variant in this study had a high viral load accompanied by fast decline
of CD4+ T cells, which was consistent with described previously rapid
disease progression of HIV-1 superinfection (Gottlieb et al., 2004,
2007b; Grobler et al., 2004; Jost et al., 2002; Liu et al., 1997; Sagar et
al., 2003). Infectionwith multiple viral variants dramatically increases
the overall viral diversity and may lead to recombinant viral variantswithin a short period of time. It is likely that multiple viral variants
might contribute to fast exhaustion of immune response and a
reduced capacity of the immune system to contain viral replication.
While elevated levels of proviral diversity and diversiﬁcation in cases
with multiple viral variants are readily predicted, no difference in the
length of variable loops or number of PNGS was found between HIV-1
subtype C infections with single or multiple viral variants except V4
reduction in both 1811 and 5018 cases. Overall, these ﬁndings are
Fig. 5. Intra-patient viral diversity in gp120. Mean values±standard deviation of pairwise maximum likelihood nucleotide distances are shown. The timeline shows days from
detected seroconversion. (A) Individual trajectories of viral diversity in gp120. Numbers within boxes correspond to subject cases. The extent of total viral diversity per time point per
subject is shown by crosses. The intra-cluster diversity in subjects 1811 and 5018 is designated by triangles (recombinant sequences are removed). Dotted lines with arrows indicate
initiation of ART. (B) Levels of proviral diversity in gp120 between subjects with slow (ﬁlled circles) and fast (open circles) decline of viral RNA. (C) Viral diversity within groups
deﬁned on viral RNA decline, fast and slow decline of viral RNA. The slow decline group is presented by uncorrected distances (deﬁned as total intra-patient pairwise distances) and
cluster-corrected distances (sequences within clusters used separately, no recombinants included). Analysis was performed for two time intervals: 0 to 200 days and 201+ days after
seroconversion. Comparison between groups is performed by t-test or Mann–Whitney Rank Sum Test (shown with ⁎).
54 V. Novitsky et al. / Virology 383 (2009) 47–59consistent with previous reports on infections with multiple viral
variants in HIV-1 subtype C (Coetzer et al., 2007; Grobler et al., 2004;
Williamson et al., 2008), although most previous studies did not
separate infections originating from multiple donors and infections
with diversiﬁed viruses from a single donor. In Tanzania, the
frequency of HIV-1 infections with multiple viral variants ranged
from 9% to 19% depending on the risk (Herbinger et al., 2006), and was
up to 25% in a high-risk cohort (McCutchan et al., 2004). Whether
frequency of multiple infections differs between HIV-1 subtypes is still
unknown, as well as the mechanistic reason for HIV-1 infections with
multiple viral variants.What is important is that HIV-1 infections withmultiple viral variants present an additional challenge for vaccine
development.
Results of this study suggest the existence of differential
pathways of viral evolution during the early phase of HIV-1 subtype
C infection. Our data support the idea that viral population is
relatively homogeneous at the time of seroconversion (Gottlieb
et al., 2007a; Shankarappa et al., 1999; Zhu et al., 1993), unless
subjects are infected with more than a single viral variant, in which
case virus population is predictably heterogeneous. We report
different patterns of viral evolution dependent on the decline of
viral RNA and the early viral RNA set point, which is consistent with
Fig. 6. Diversiﬁcation of viral gp120 in acute HIV-1 subtype C infection. Mean values±standard deviation are shown. Viral diversiﬁcation at each time point was compared to the per-
subject MRCA sequence reconstructed from viral quasispecies at all time points (red triangle), and consensus sequence reconstructed from the earliest available quasispecies (green
square). The timeline shows days from detected seroconversion. (A) Individual trajectories of viral diversiﬁcation. Numbers within boxes correspond to subject cases. Dotted lines
with arrows indicate initiation of ART. (B) Viral diversiﬁcation from MRCA that was reconstructed from viral quasispecies is compared between groups deﬁned on viral RNA
phenotype, fast and slow decline of viral RNA. The slow decline group is presented in twoways: by uncorrected distances (deﬁned as total intra-patient pairwise distances to MRCA)
and cluster-corrected distances (deﬁned as intra-cluster pairwise distances to MRCA, no recombinants were included). Analysis was performed for two time intervals: 0 to 200 days
and 201+ days after seroconversion. Comparison between groups is performed by t-test or Mann–Whitney Rank Sum Test (shown with ⁎).
55V. Novitsky et al. / Virology 383 (2009) 47–59the assumption that higher levels of viral replication cause higher
levels of viral diversity and diversiﬁcation over time. In subjects
with suboptimal suppression of viral replication after seroconver-
sion we observed higher viral diversiﬁcation. In contrast, in subjects
with efﬁcient suppression of viral replication, at least by 200 days
after seroconversion, the diversiﬁcation of virus was lower. Three
out of four subjects with more diversiﬁed proviral gp120 dropped
CD4+ T cell count below 200 within the ﬁrst year after seroconver-
sion and initiated ARV treatment, while none of four subjects with
lower proviral diversity did. Whether ARV treatment alters proviraldiversity in HIV-1 subtype C gp120 needs to be addressed in future
studies.
We found no or minimal length variation in variable loops and
the number of PNGS in gp120 during the ﬁrst year after
seroconversion, which is consistent with the recent report from
South Africa (Coetzer et al., 2007). In contrast, studies from Zambia
suggested preferential transmission of HIV-1 subtype C with
compact variable loops and a reduced number of PNGS (Derdeyn
et al., 2004; Li et al., 2006a). Transmission of viruses with shorter
and less glycosylated Env implies a gradual increase in variable loop
Fig. 7. Changes in the length of V-loops and the number of PNGS in acute HIV-1 subtype C infection are presented as a difference betweenmean value at a given time point and earliest
available time point. Variable loops are shown by red (V1), green (V2), yellow (V3), white (V4), and gray (V5) colors. The timeline shows days from detected seroconversion. Numbers
above boxes correspond to subject cases. (A) Evolution of length of variable loops in gp120. (B) Evolution in number of PNGS within V-loops in gp120.
56 V. Novitsky et al. / Virology 383 (2009) 47–59length and in the number of PNGS over the course of infection,
which has not been conﬁrmed experimentally. While shorter
variable loops in natural subtype C infections are more likely to
induce broad NeuAb, no association between the number of PNGS
and induction of NeuAb was reported (Rademeyer et al., 2007). The
loop length and the number of PNGS differ between HIV-1 subtypes.
For example, newly transmitted subtype B viruses have longer and
more glycosylated gp120 than newly transmitted subtype C viruses
(Li et al., 2006b), and V1V2 loops are shorter in subtype A infections
(Chohan et al., 2005). However within HIV-1 subtype C no
difference in the length of variable loops between newly trans-mitted and chronic viruses has been reported (Li et al., 2006b),
which is consistent with our ﬁndings. The number of PNGS in
variable loops of Env showed minimal ﬂuctuations and no clear
patterns of intra- and inter-subject variation of PNGS were observed
over the ﬁrst year of HIV-1 subtype C infection.
In summary, the results of the study suggest that the frequency of
HIV-1 subtype C infections with more than a single viral variant is not
rare and provide a characterization of the proviral evolution of gp120
in an early phase of HIV-1 subtype C infection. We found differential
pathways of viral evolution dependent on viral replication during the
ﬁrst 200 days after. There was minimal evolution of the variable loop




Eight cases of acute HIV-1 subtype C infections were identiﬁed as
part of a primary HIV-1 infection study in Botswana (Novitsky et al.,
2007b), approved by the Institutional Review Boards in Botswana
and the US. A positive HIV-1 RT-PCR accompanied by a negative
HIV-1 serology, the RNA+Ab− status was used as inclusion criteria for
enrollment. Following identiﬁcation as being acutely infected with
HIV, participants had weekly and bi-weekly visits for the ﬁrst
4 months, and monthly visits for the following 8 months. The
analyzed subjects included 2 males and 6 females whose age
ranged from 20 to 53 years old. The mean value of viral RNA peak
was 6.25±0.92 log10 copies/ml. Two patterns in evolution of viral RNA
and CD4+ T cells were evident suggesting slow or fast decline of viral
RNA during the ﬁrst two post-seroconversion months (5.47±0.46 vs.
3.72±0.65 log10; p=0.005). While the viral RNA peaks did not differ
between subjects with slow or fast decline of viral RNA (6.79±0.97
log10 vs. 5.72±0.53 log10 for slow and fast decline, respectively; 95% CI
for difference of means: −0.28 to 2.41; p=0.10), the rates of viral
RNA decline measured by slopes were different between groups
(−0.0128±0.0058 log10 per day vs −0.0275±0.0082 log10 per day for
groups with slow and fast RNA decline, respectively; p=0.03). The
assumption was made that the peak of viral RNA should decline by
day 50 after seroconversion. The early viral RNA set point deﬁned as
mean±standard deviation of plasma RNA measurements from 50 to
200 days differed between subjects with slow and fast decline of
viral RNA (Fig. 1; 5.25±0.22 vs. 3.62±0.45 log10 for slow and fast
decline of viral RNA, pb0.001). Subjects 1811, 2865, 3312, and 5018
showed slow decline of viral RNA and a high early viral RNA set
point. Subjects 3430, 3505, 3603, and 5582 demonstrated fast
decline of viral RNA and a low early set point. The distinct viral RNA
phenotypes were associated with different CD4+ T cell count in
subjects (271±59 vs. 491±38; 95% CI for difference of means −305
to −134; pb0.001, and 250±71 vs. 482±57; 95% CI for difference of
means −344 to −121; p=0.002 for CD4 comparisons between
groups during the ﬁrst 2 months and 2 to 6 months, respectively).
Access to ART was free of charge if participants' CD4+ T cell count
dropped below 200 cells/mm3, or if they had an AIDS-deﬁning
illness. Three out of four subjects with slow decline of viral RNA
dropped their CD4+ T cell count below 200 and initiated ART within
the ﬁrst year after seroconversion. None of four subjects with fast
decline of viral RNA dropped CD4+ T cells below 200 and did not
initiate ART within the ﬁrst post-seroconversion year.
Single genome ampliﬁcation and sequencing
The proviral DNA was ampliﬁed from PBMC isolated at multiple
visits from seroconversion up to 440 days thereafter. In this study,
time 0 corresponded to the time of seroconversion. A strategy of
single-genome ampliﬁcation by limiting dilutions and sequencing
close to the recently published method (Salazar-Gonzalez et al., 2008)
with some modiﬁcations was employed. The targeted region of
proviral gp120 spanned the V1 loop to the C terminus end of gp120,
V1C5, and corresponded to nucleotide positions 6615 to 7757 of HXB2
(amino acids 131 to 511 in relation to the gp120 CDS in HXB2).
Amplicons were puriﬁed by Exo-SAP (Dugan et al., 2002), and
sequenced directly on the ABI 3730 DNA Analyzer using the BigDye
technology. About 10 viral sequences per subject per time point were
analyzed. The obtained sequences were tested by HYPERMUT v.2.0
(Rose and Korber, 2000) and hypermutated sequences were excluded.
Diversity of quasispecies, divergence from the most recent commonancestor (MRCA) and earliest viral quasispecies over time, length of
variable loops, and number of PNGS were longitudinally character-
ized. Sequences from ARV-treated subjects 1811, 2865, and 3312 were
included in the analysis. Time of ART initiation is indicated by arrows
in Figs. 5 and 6.
Diversity and divergence
Alignment of nucleotide sequences was performed and reﬁned by
Muscle (Edgar, 2004) followed by a manual adjustment in BioEdit
(Hall, 1999). The maximum-likelihood (ML) method was used to
estimate pairwise nucleotide distances. PAUP⁎ version 4.0 (Swofford,
2003) and Modeltest version 3.7 (Posada and Buckley, 2004; Posada
and Crandall, 1998) with the Akaike information criterion were
utilized to identify an appropriate substitution model. The identiﬁed
substitution model was used in PAUP⁎ to estimate ML-corrected
pairwise distances. The proviral diversity per subject per time point
was computed as a mean value±standard deviation of pairwise
distances between proviral quasispecies at the given time point. The
mean values and standard deviations are shown in ﬁgures as fractions
of 1, and presented as percentages in the text for convenience.
Quantiﬁcation of viral diversiﬁcation was performed by using a mean
value±standard deviation of pairwise distances between viral
quasispecies at the given time point and a subject's MRCA or
consensus sequence of the viral quasispecies from the earliest time
point. The MRCA for each subject was reconstructed at the basal node
of viral quasispecies collected at all time points using ML criteria in
PAUP⁎. The alignment was gap-stripped, and single sequences from
other seven subjects were used as outgroups, as described elsewhere
(Learn et al., 2002). The majority consensus sequence for the earliest
quasispecies was built in BioEdit.
Phylogenetic analysis
The genealogy reconstruction of the proviral sequences was
implemented in PhyML (Guindon and Gascuel, 2003) using the HKY
model of nucleotide substitution. The branching topology of gener-
ated maximum-likelihood phylogenetic tree in PhyML was compar-
able with NJ trees generated by MEGA4. Only maximum likelihood
trees visualized by FigTree v1.1.2 (Rambaut, 2008) are presented. For
HIV-1 subtyping purpose, a total of 35 reference sequences represent-
ing HIV-1 M group subtypes from A to H from Los-Alamos HIV
Sequence Database (http://www.hiv.lanl.gov/) were included in the
analysis.
Statistical methods
Data are summarized with means±standard deviations and
correlations. Comparisons between groups, including grouping of
subjects with slow and fast decline of viremia, were based on t-tests
and Mann–Whitney Rank Sum tests for continuous and binary
outcomes, respectively. All reported p-values are 2-sided.
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